AMBU B Ambu A/S Class B

Launch of Long-Term Incentive Plan

Launch of Long-Term Incentive Plan

In accordance with the Remuneration Policy approved at the annual general meeting on 17 December 2019, Ambu A/S has today launched a long-term incentive plan for the Executive Board. In addition, 186 key employees in the global organisation are enrolled in the plan on similar terms. In the plan, the Executive Board receives a total of up to 66,410 Performance Share Units (PSUs) while key employees receive a total of up to 139.266 PSUs. Each PSU may at vesting – on 1 January 2024 – be converted to one B share in Ambu A/S subject to the terms of the program.

The plan covers the financial year 2020/21, and the PSUs will be allocated based on how targets for organic revenue growth for 2020/21 are achieved. Final allocation will be within 0-100% of the grant. The aggregate fair market value of the total allocation at the time of grant equals DKK 43m.

Depending on the future development of the share price of the Ambu B share, the value of the PSUs will, at the time of vesting, be capped at four times the annual base salary measured at the time of the grant.

The share price used for calculating the number of PSUs has, in accordance with the policy, been the day of the annual general meeting in Ambu A/S in December 2020 and the following four trading days (9-15 December 2020).

CONTACTS

Investors

Nicolai Thomsen, Director, Investor Relations, /

Media

Mikkel Trier Wagner, Director, Corporate Communications, /

Attachment



EN
29/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Ambu AS: 1 director

A director at Ambu AS bought 2,800 shares at 15.412USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK144.00) - Possibly isolated softness

Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch